AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

United Kingdom 2019: Triple-Negative Breast Cancer Key Opinion Leader (KOL) Interview - ResearchAndMarkets.com

November 21, 2019

DUBLIN--(BUSINESS WIRE)--Nov 21, 2019--

The “Triple-Negative Breast Cancer KOL Interview - UK” report has been added to ResearchAndMarkets.com’s offering.

A UK-based key opinion leader providers insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for triple-negative breast cancer. Diagnostic testing, biomarker disease segmentation, and unmet needs are also discussed. Key pipeline assets highlighted include balixafortide, capivasertib, ipatasertib, Keytruda, sacituzumab govitecan, trastuzumab deruxtecan, and veliparib.

Highlights from the interview include:

For more information about this report visit https://www.researchandmarkets.com/r/90eggk

View source version on businesswire.com:https://www.businesswire.com/news/home/20191121005772/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

KEYWORD: UNITED KINGDOM EUROPE

INDUSTRY KEYWORD: PHARMACEUTICAL HEALTH ONCOLOGY

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 11/21/2019 11:56 AM/DISC: 11/21/2019 11:56 AM

http://www.businesswire.com/news/home/20191121005772/en